ERBB2 and neoplasm: Considering these features, the American Society of Clinical Oncology (ASCO) guideline suggests that neoadjuvant chemotherapy (NCT) may be administered to ER+/HER2- patients if the tumor stage is such that chemotherapy will be administered regardless of surgical timing.